Doubling possible: Using artificial intelligence! Deutsche Telekom, NetraMark Holdings, Kontron, and 1&1

Kontron – Annual figures depress the share price

Artificial intelligence is accelerating innovations in transportation, industry, medicine, and security, paving the way for a networked, automated future. 5G also enables decentralized data processing (edge computing). Kontron AG describes itself as one of the leading providers of IT services and solutions in Central and Eastern Europe. The Company is focused on the prospering Internet of Things (IoT) market. The business is divided into three segments: IT Services, IOT Solutions Europe and America. These segments provide secure and connected solutions through a combined portfolio of hardware, middleware, and services in the areas of the Internet of Things and Industry 4.0.

For 2024, Kontron reports a 37% increase in revenues to EUR 1.685 billion, with EBITDA also rising by 52% to EUR 191.8 million. Profit improves from EUR 77.7 million to EUR 90.7 million. This corresponds to EUR 1.47 after 1.23 per share; the dividend will be raised by EUR 0.10 to 0.60. In 2025, Kontron expects revenues of EUR 1.9 to 2.0 billion, with EBITDA of at least EUR 220 million. There is also a negative side to report. In particular, analysts have highlighted the weakness in the solar inverter business as a burden. After a 40% increase in the share price in the last six months, shareholders are using the good figures to realize profits. Analysts at Jefferies and Pareto see price targets of EUR 27 and EUR 28, respectively. With a P/E ratio of 14 in 2025, the Kontron share is not too expensive at EUR 22.90.

NetraMark Holdings – Making the best use of artificial intelligence

Among many other applications, big data and artificial intelligence (AI) applications are also revolutionizing the clinical phases of drug approval by accelerating processes, reducing costs, and significantly increasing the success rate. AI can analyze large amounts of data from electronic health records, genomic data, and patient registries to identify suitable clinical trial participants faster and more accurately. This significantly reduces recruitment time and improves accuracy.

The Canadian technology company NetraMark Holdings Inc. (AIAI) develops innovative solutions for the pharmaceutical industry by using Generative Artificial Intelligence (Gen AI). The pharmaceutical industry is increasingly using artificial intelligence to make clinical trials more efficient and accurate. The results so far indicate a quantum leap, as the NetraAI 2.0 platform addresses one of the most pressing challenges in clinical research: Finding the interface between efficacy and feasibility. Recent studies show that the market for artificial intelligence in clinical research is currently experiencing dynamic growth. In 2021, this sector generated a turnover of approximately USD 1.3 billion, and this figure is expected to reach USD 5.6 billion by 2029. This corresponds to a compound annual growth rate (CAGR) of 19.9% per annum.

CEO George Achilleos knows that a high percentage of all clinical trials, especially in Phases 2 and 3, fail. However, by this point, the biotech and pharmaceutical industries have already invested a significant amount of money. NetraMark is working hard to revolutionize the results of these studies through improved design and evaluation methods. Investors applaud the success of the Canadians, as AIAI shares have already increased tenfold since September 2024. The share price is currently consolidating between CAD 1.10 and 1.20. Between December and March, some options and warrants were exercised. This filled the coffers by over CAD 3 million and increased the share count to 79.76 million. The market capitalization of just over CAD 100 million is still quite modest for the high-tech approach. The rally is likely to start again soon.

Here is the link to the interview on the platform THE MARKETS ONLINE with CEO George Achilleos and Lyndsay Malchuk.

Deutsche Telekom and 1&1 – Conversion to 5G is in progress

Deutsche Telekom and 1&1 are working hard to convert their networks to the new 5G standard. The combination of AI and 5G will usher in a new digital era in the mobile business. It will accelerate many innovations in transportation, industry, medicine, and security – and pave the way for a connected, automated future. Autonomous driving relies on a great deal of environmental data, and fast pattern recognition is essential for avoiding accidents.

Deutsche Telekom is comprehensively integrating artificial intelligence into its business processes to increase efficiency and develop new services. AI optimizes the operation and maintenance of telecommunications networks by analyzing data and proactively responding to possible disruptions. Virtual assistants and chatbots support customer inquiries around the clock, improve service quality, and relieve employees. In the area of cyber security, AI-based systems detect and fend off threats in real-time, increasing network security. By 2027, Deutsche Telekom hopes to generate additional revenues of around EUR 1.5 billion and realize cost savings of EUR 700 million with AI. The DTE share is a star in the DAX 40 index, with a 50% increase in the last 12 months. Stay on board!

The latest developments at United Internet and its subsidiary 1&1 highlight the challenges in the highly competitive mobile market. 1&1 faces the difficult task of migrating its mobile customers to a new 5G network. This migration is part of a comprehensive plan to build its own mobile network that will ensure long-term independence from partners such as Vodafone. Analysts at Goldman Sachs recently expressed concerns about the unexpectedly poor outlook for 2025. 1&1 plans to achieve a stable contract base in 2025 and to maintain service revenues at the EUR 3.3 billion level. However, a slight decline in EBITDA to around EUR 570 million is expected. The 1&1 share has recovered well from its lows of EUR 11 to over EUR 15. A 2025 P/E ratio of 9 is not too high for the internet service provider!

Advances in AI-powered analysis could lead to personalized drug trials in the future, enabling therapeutic approaches tailored to specific patient groups. At the same time, AI has the potential to make the entire approval process more efficient and transparent. NetraMark Holdings is on the verge of establishing itself as one of the first leading AI innovators in the clinical approval phases – an extremely exciting development!